These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 26874466)

  • 21. Chimeric T-cell receptors: new challenges for targeted immunotherapy in hematologic malignancies.
    Biagi E; Marin V; Giordano Attianese GM; Dander E; D'Amico G; Biondi A
    Haematologica; 2007 Mar; 92(3):381-8. PubMed ID: 17339188
    [TBL] [Abstract][Full Text] [Related]  

  • 22. From humble beginnings to success in the clinic: Chimeric antigen receptor-modified T-cells and implications for immunotherapy.
    Firor AE; Jares A; Ma Y
    Exp Biol Med (Maywood); 2015 Aug; 240(8):1087-98. PubMed ID: 25956686
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Hematologic Malignancies: Plasma Cell Disorders.
    Dhodapkar MV; Borrello I; Cohen AD; Stadtmauer EA
    Am Soc Clin Oncol Educ Book; 2017; 37():561-568. PubMed ID: 28561703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. T cell senescence and CAR-T cell exhaustion in hematological malignancies.
    Kasakovski D; Xu L; Li Y
    J Hematol Oncol; 2018 Jul; 11(1):91. PubMed ID: 29973238
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Chimeric antigen receptor T cells immunotherapy: challenges and opportunities in hematological malignancies.
    El-Khazragy N; Ghozy S; Emad P; Mourad M; Razza D; Farouk YK; Mohamed NA; Ahmed MK; Youssef T; Bahnasawy YM; Elmasery S
    Immunotherapy; 2020 Dec; 12(18):1341-1357. PubMed ID: 33148070
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Chimaeric antigen receptor T-cell therapy for tumour immunotherapy.
    Sha HH; Wang DD; Yan DL; Hu Y; Yang SJ; Liu SW; Feng JF
    Biosci Rep; 2017 Feb; 37(1):. PubMed ID: 28053197
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Driving CAR-based T-cell therapy to success.
    Jena B; Moyes JS; Huls H; Cooper LJ
    Curr Hematol Malig Rep; 2014 Mar; 9(1):50-6. PubMed ID: 24488441
    [TBL] [Abstract][Full Text] [Related]  

  • 28. [Chimeric antigen receptor T cell (CAR-T) therapy for refractory/relapsed hematological malignancy].
    Hiramatsu H
    Rinsho Ketsueki; 2018; 59(10):1948-1954. PubMed ID: 30305496
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Advances in immunotherapy of hematological malignancies by using chimeric antigen receptor-modified lymphocytes].
    Xu XJ; Zhao HZ; Tang YM
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2013 Apr; 21(2):521-5. PubMed ID: 23628068
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric Antigen Receptors Modified T-Cells for Cancer Therapy.
    Dai H; Wang Y; Lu X; Han W
    J Natl Cancer Inst; 2016 Jul; 108(7):. PubMed ID: 26819347
    [TBL] [Abstract][Full Text] [Related]  

  • 31. T-Cell Immunotherapies Targeting Histocompatibility and Tumor Antigens in Hematological Malignancies.
    Janelle V; Rulleau C; Del Testa S; Carli C; Delisle JS
    Front Immunol; 2020; 11():276. PubMed ID: 32153583
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Going viral: chimeric antigen receptor T-cell therapy for hematological malignancies.
    Gill S; June CH
    Immunol Rev; 2015 Jan; 263(1):68-89. PubMed ID: 25510272
    [TBL] [Abstract][Full Text] [Related]  

  • 33. CD19-Targeted T Cells for Hematologic Malignancies: Clinical Experience to Date.
    Davila ML; Sauter C; Brentjens R
    Cancer J; 2015; 21(6):470-4. PubMed ID: 26588678
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Current status of chimeric antigen receptor therapy for haematological malignancies.
    Maude S; Barrett DM
    Br J Haematol; 2016 Jan; 172(1):11-22. PubMed ID: 26560054
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Development of innovative T-cell immunotherapy for hematological malignancies].
    Ochi T
    Rinsho Ketsueki; 2019; 60(7):824-833. PubMed ID: 31391373
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Prospects for adoptive immunotherapy of pancreatic cancer using chimeric antigen receptor-engineered T-cells.
    Alrifai D; Sarker D; Maher J
    Immunopharmacol Immunotoxicol; 2016; 38(1):50-60. PubMed ID: 26473647
    [TBL] [Abstract][Full Text] [Related]  

  • 37. CD19-targeted CAR T-cell therapeutics for hematologic malignancies: interpreting clinical outcomes to date.
    Park JH; Geyer MB; Brentjens RJ
    Blood; 2016 Jun; 127(26):3312-20. PubMed ID: 27207800
    [TBL] [Abstract][Full Text] [Related]  

  • 38. CD19 chimeric antigen receptor T cell therapy for the treatment of B cell lineage acute lymphoblastic leukemia.
    Chen R; Song XT; Chen B
    Discov Med; 2015 Oct; 20(110):185-90. PubMed ID: 26562471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Adverse Effects Associated with Clinical Applications of CAR Engineered T Cells.
    Badieyan ZS; Hoseini SS
    Arch Immunol Ther Exp (Warsz); 2018 Aug; 66(4):283-288. PubMed ID: 29427174
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Generating and Expanding Autologous Chimeric Antigen Receptor T Cells from Patients with Acute Myeloid Leukemia.
    Kenderian SS; June CH; Gill S
    Methods Mol Biol; 2017; 1633():267-276. PubMed ID: 28735493
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.